A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This is a phase I open label study to evaluate safety and efficacy of P1446A-05 in subjects
with advanced refractory malignancies. Subjects of solid tumors or hematologic malignancies
will be included. This is a dose escalation study following an accelerated titration design.
It is expected that around 50 subjects would be enrolled in the study.Safety assessment will
be conducted on the basis of vital signs, physical examination and laboratory investigations
undertaken at regular intervals as per the schedule.